Axiom ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-3145-PF5B

PRO-BBX30 · Lot T-DEA-0098
Issued Oct 3, 2026 · v1
Verify: D8F8-C310-D2F7

SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

L1	L2	L3	L4	L8
Identity	Purity	Net Peptide Content	Sterility	Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A · right

Brand	**Precise Research Only**	Product	**PRO-BBX30**
Lot / Batch	**T-DEA-0098**	Label Claim	**BPC-157 10 mg + TB-500 10 mg + Cartalax 10 mg**
Matrix	**lyophilized powder**	Sample Count	**1**
Cap Color	**Black**	Crimp Color	**Silver / Aluminum**
Contents Color	**White**	Seal Intact	**Yes**
Condition	**sealed, intact**	Received	**Sep 24, 2026**
Sampling	**client submitted**		

Test Results

Test	Specification	Result	
Identity research screen	every declared component within ±1 Da of its own theoretical mass	3 of 3 components confirmed	PASS
Purity research screen	each declared component at or above its own locked purity criterion	99.64%	PASS
Net Peptide Content research screen	each declared component within its own locked content criterion, at the declared ratio	31.73 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-3145-PF5B

PRO-BBX30 · Lot T-DEA-0098
Issued Oct 3, 2026 · v1
Verify: D8F8-C310-D2F7

SCAN TO VERIFY

Layer Results

1 Identity

LC-MS (ESI+)

3 of 3 components confirmed
every declared component within ±1 Da of its own theoretical mass

PASS

Component	Its criterion	Observed	Status
BPC-157	1419.556 Da · acceptance ±1 Da · average	1419.686 Da · mass error +0.13 Da (91.6 ppm)	PASS
TB-500 (Thymosin B4)	4963.506 Da · acceptance ±1 Da · average	4963.541 Da · mass error +0.035 Da (7.1 ppm)	PASS
Cartalax	333.297 Da · acceptance ±1 Da · average	333.407 Da · mass error +0.11 Da (330 ppm)	PASS

Acceptance **within ±1 Da** Vial A **3 of 3 components confirmed**

2 Purity

RP-HPLC 214nm (USP 621)

99.64%
each declared component at or above its own locked purity criterion

PASS

Component	Its criterion	Observed	Status
BPC-157	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.64%	PASS
TB-500 (Thymosin B4)	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.33%	PASS
Cartalax	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.94%	PASS

Acceptance **Each component NLT 99.25 area %** Vial A **99.64% · PASS**

3 Net Peptide Content

Quantitative HPLC vs reference std

31.73 mg
each declared component within its own locked content criterion, at the declared ratio

PASS

Component	Its criterion	Observed	Status
BPC-157	9–11 mg (10 mg ±10%)	10.66 mg	PASS
TB-500 (Thymosin B4)	9–11 mg (10 mg ±10%)	10.67 mg	PASS
Cartalax	9–11 mg (10 mg ±10%)	10.4 mg	PASS

Ratio, in the table's component order: observed **1.00 : 1.00 : 0.98** against declared **1.00 : 1.00 : 1.00** · source Axiom SPEC-CONTENT-001

Target **30 mg (±10%)**

4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected
Rapid PCR screen

PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-3145-PF5B

PRO-BBX30 · Lot T-DEA-0098
Issued Oct 3, 2026 · v1
Verify: D8F8-C310-D2F7

SCAN TO VERIFY

8 Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected
no fentanyl or analog at or above 1 ng/mg

PASS

Result	**Not detected**	Detection limit	**1 ng/mg**
Analytes screened	**Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)**	Source container	**A**

Reporting Scope & Limitations

`[Sterility · Rapid PCR]` Rapid PCR screen for microbial DNA. It detects DNA from live and dead organisms and is not a USP <71> sterility test or a USP <61> count. Full USP <71> sterility testing is available as an add-on.

`[Fentanyl Screen]` Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	**Alana Reeves**	Analyst Signature	**ed25519:8f2b3a723f7adbeef3f67655...**
Technical Reviewer	**Michael Niles**	Reviewer Signature	**ed25519:edc47bcc2654e392c9297f23...**
Laboratory Director	**Daniel Brennan**	Director Signature	**ed25519:115d1ddcd50dc3836fe50074...**

Testing is performed within Axiom's laboratory network under Axiom's methods. Every result is reviewed and released by Axiom, which issues and is responsible for this certificate. Axiom Analytics does not hold ISO/IEC 17025 accreditation. Samples are identified to the testing laboratory by an internal lot ID only. The method status of each result is shown beside it.

Each signature is an Ed25519 signature over the SHA-384 hash of this report. Scan the QR code or verify it yourself at https://axiomanalyticslab.com/verify/AX-2026-3145-PF5B.

Presentation corrected 2026-10-04; results and signatures unchanged.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: e60405a1df78e7f77190c9a826474b3fadd8744f1138345e54b1e812de59701c...
Seal: ed25519:e0c49e4836e4541aa962a4eeb311d2f23c1ff312...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.